RE:RE:CAR-T updateThe immunosuppressive tumor microenvironment and physical tumor barriers, such as the tumor stroma, can restrict the infiltration and migration of CAR-T cells, limiting their effectiveness in treating solid tumors. One main reason is the lack of relevant receptors on CAR-T cells that match the chemokines secreted by solid tumors, which hinders their homing ability to the tumor site.
ONCY and Mayo Clinic's Dr. Richard Vile have demonstrated that CAR-T therapy "seeded" with pelareorep is effective in having pelareorep traffick, or provide a "homing" effect, for the CAR-T/pelareorep combination to the travel to the solid tumor site and effect both the CAR-T and pelareorep's immunotherapeutic activity. Then by adding a follow-up pelareorep "boost", a durable and 'curative' therapeutic effect was subsequently demonstrated.